AMNOG
The Arzneimittelmarkt-Neuordnungsgesetz (AMNOG, English translation: "Pharmaceuticals Market Reorganisation Act") is a German law relating to the marketing of pharmaceutical products in Germany. It requires drug manufacturers to submit evidence to the Federal Joint Committee (Germany) that shows whether their new products have an added benefit compared to previous products.[1] It is credited with reducing the cost of healthcare in Germany.[2]
References
[edit]- ↑ "AMNOG - evaluation of new pharmaceutical". GKV-Spitzenverband. 2014. Retrieved 27 May 2014.
{{cite web}}: CS1 maint: deprecated archival service (link) - ↑ Olga Khazan (22 May 2014). "Why Medicine Is Cheaper in Germany". The Atlantic.
See also
[edit]  | This article about German law is a stub. You can help Wikipedia by adding missing information. |